Gastrointestinal Diseases
Recent clinical, regulatory, research and industry developments relating to this disease.
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning.
Enteric neuropathy and the vagus nerve: Therapeutic implications.
Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products.
The gut microbiome in disorders of gut-brain interaction.
Microbiota in Autism Spectrum Disorder: A Systematic Review.
NOD-like Receptor Signaling Pathway in Gastrointestinal Inflammatory Diseases and Cancers.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q1 2027.
- Q1 2027A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)
- Q1 2030AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
Clinical MilestonesViewHide
- 2026-07-06AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCERResults expected Q1 2030
- 2026-07-02A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)Results expected Q1 2027
- 2026-07-06ClinicalAN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCERResults expected Q1 2030
- 2026-07-02ClinicalA FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)Results expected Q1 2027
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Imatinib Accord is indicated for the treatment of adult and paediatric patients with new… (2013)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Gastrointestinal Microbiome15
- Gastrointestinal Diseases11
- Brain3
- Brain-Gut Axis3
- Gastrointestinal Tract3
- Probiotics3
- Diet2
- Digestive System Physiological Phenomena2
Leading journals6
- Gut microbes4
- Gastroenterology3
- International journal of molecular sciences3
- Nutrients3
- The New England journal of medicine3
- Microbiome2
Leading researchers8
- Bonaz B3
- Gibson GR3
- Roberfroid M2
- Rowland I2
- Stahl B2
- Vanner S2
- Adams JB1
- Adelman DC1
Affiliations (unnormalised)6
- School of Medicine3
- College of Pharmacy2
- Farncombe Family Digestive Health Research Institute2
- Johns Hopkins University2
- McMaster University2
- Translational Research Center for Gastrointestinal Disorders (TARGID)2
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Gastrointestinal diseases are disorders affecting any part of the gastrointestinal tract, from the esophagus to the rectum. The category includes a broad range of luminal conditions and is studied across physiology, microbiology, metabolism, immunology, etiology, and prevention and control.
The grounding supports multiple contributing causes and associations rather than a single aetiology. These include chemically induced disease, microbiome-related changes such as dysbiosis, and diet-related influences on the gut ecosystem.
The literature emphasizes disruption of gut homeostasis and host-microbe interactions as central mechanisms. Changes in the gastrointestinal microbiome, microbial fermentation products such as short-chain fatty acids, and related effects on epithelial integrity, mucosal immune function, and signal transduction are repeatedly implicated. The brain-gut axis is also a studied mechanism in this disease group.
Dietary patterns and environmental factors are associated with altered gut microbiota and disease-prone states. Dysbiosis, in which potentially harmful microorganisms predominate over health-associated microbes, is described as a risk state for gastrointestinal disease. The grounding also supports chemically induced exposure as a risk-related category.
Management is described at the modality level and includes therapy, prevention and control, and microbiota-directed approaches. Probiotics and prebiotics are presented as microbiota-management tools used to modulate the gut microbiota and support intestinal health. Dietary intervention is also a relevant treatment category in the literature.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.